Form 4: Marinus Pharmaceuticals CFO Steven Pfanstiel Disposes of Shares and Stock Options Following Merger Agreement

Following the merger agreement between Marinus Pharmaceuticals and Immedica Pharma AB, CFO Steven Pfanstiel reports the disposal of common stock and stock options.

Summary

• Steven Pfanstiel, CFO and COO of Marinus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The filing is related to the merger agreement between Marinus Pharmaceuticals and Immedica Pharma AB, where Immedica will acquire Marinus.
• Pfanstiel disposed of 17,303 shares of common stock at $0.55 per share on February 7, 2025.
• He also disposed of 62,470 shares underlying Restricted Stock Units (RSUs) on February 11, 2025, which were terminated for a cash payment based on the offer price of $0.55 per share.
• Additionally, Pfanstiel's out-of-the-money stock options were terminated without any payment as per the merger agreement.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports transactions related to a previously announced merger agreement. The disposal of shares and termination of options are expected outcomes of the merger.

Negatives

• The CFO's stock options were terminated without payment, indicating they were out-of-the-money at the merger price of $0.55 per share.

Future Outlook

The merger between Marinus Pharmaceuticals and Immedica Pharma AB is expected to proceed, resulting in the acquisition of Marinus' common stock at $0.55 per share.

Industry Context

This announcement reflects a merger and acquisition activity within the pharmaceutical industry, where companies are often acquired for their assets, technologies, or market positions.

Comparison to Industry Standards

• Comparing this acquisition to other pharmaceutical mergers, the offer price of $0.55 per share represents a specific valuation determined by the involved parties.
• Similar transactions, such as the acquisition of smaller biotech firms by larger pharmaceutical companies, often involve a premium over the target's current market price.
• The termination of out-of-the-money stock options is a standard practice in merger agreements, as these options hold no intrinsic value at the acquisition price.

Stakeholder Impact

• Shareholders received $0.55 per share as part of the merger agreement.
• Employees with stock options that were out-of-the-money did not receive any payment for those options.

Key Dates

Keywords

Form 4, Marinus Pharmaceuticals, Immedica Pharma AB, Merger Agreement, Steven Pfanstiel, Beneficial Ownership, Stock Options, Restricted Stock Units, MRNS